Invention Application
- Patent Title: Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
-
Application No.: US13604228Application Date: 2012-09-05
-
Publication No.: US20130109073A1Publication Date: 2013-05-02
- Inventor: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant Address: US NJ Morris Plains
- Assignee: IBC PHARMACEUTICALS, INC.
- Current Assignee: IBC PHARMACEUTICALS, INC.
- Current Assignee Address: US NJ Morris Plains
- Main IPC: C12N9/96
- IPC: C12N9/96

Abstract:
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes.
Public/Granted literature
- US09617531B2 Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock Public/Granted day:2017-04-11
Information query